Integer Holdings Corporation
PE-OWNED
Acquired by KKR
What PE Will Likely Do
Increased pricing for medical device contract manufacturing services as KKR seeks to maximize margins on existing customer contracts
Reduction in R&D investment for customer product development, leading to slower innovation cycles and longer time-to-market for new medical devices
Consolidation of manufacturing facilities with closure of smaller or specialized production sites, concentrating operations in fewer locations
Deferred maintenance and calibration of precision manufacturing equipment, potentially affecting product quality consistency and FDA compliance rates
Staff reductions among specialized engineering and regulatory affairs personnel, leading to longer response times for customer technical support
Expected Timeline
“0 to 6 months months”
KKR announces 'partnership' with Integer leadership; internal communications emphasize 'operational excellence' and 'growth acceleration'; early identification of 'non-core' facilities and 'redundant' administrative functions
“6 to 12 months months”
First wave of layoffs in engineering, quality assurance, and regulatory affairs; initial facility consolidation announcements; customer-facing price increases on contract renewals; extended lead times for prototype development begin
“12 to 24 months months”
Noticeable degradation in customer service responsiveness; increased FDA warning letters or quality observations due to deferred equipment maintenance; dividend recapitalization event extracts capital; key technical talent departs
“24 to 48 months months”
Customer complaints about inconsistent product quality and missed delivery commitments escalate; Integer loses major customer contracts to competitors; bankruptcy rumors emerge as debt service burdens peak; further desperate cost-cutting including elimination of specialized manufacturing capabilities
Similar Cases
Other companies that followed a similar path after PE acquisition
What You Can Do
Actions
Medical device companies contracting with Integer should audit their supplier agreements and establish secondary manufacturing sources before service degradation begins
Healthcare systems purchasing devices manufactured by Integer should verify manufacturing location continuity and request quality metric transparency in procurement contracts
Patients and clinicians using devices produced through Integer's contract manufacturing should monitor FDA MAUDE database for increased adverse event reports suggesting quality issues
Integer employees in specialized technical roles should document proprietary knowledge and consider competitive opportunities before organizational knowledge loss accelerates
Customers should negotiate contract terms locking in pricing and service levels for 3-5 years before KKR implements aggressive pricing changes
Alternatives
Look for family-owned or employee-owned businesses